Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: interim results for ARIEL2 clinical trial
Monday, March 30, 2015: 2:35 PM
International Ballroom (Hilton Chicago)
E. M. Swisher1, A. M. Oza2, R. L. Coleman3, C. Scott4, K. Lin5, E. Dominy5, L. Maloney6, S. Goble6, R. Yelensky7 and I. McNeish8
1University of Washington, Seattle, WA, 2University Health Network, Princess Margaret Hospital, Toronto, ON, Canada, 3The University of Texas MD Anderson Cancer Center, Houston, TX, 4Royal Melbourne Hospital, Parkville Victoria, Australia, 5Clovis Oncology Inc., San Francisco, CA, 6Clovis Oncology Inc., Boulder, CO, 7Foundation Medicine Inc., Cambridge, MA, 8Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
